Incyte (INCY) Cash from Investing Activities Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.10% |
| Dec 31, 2025 | 18.29% |
| Sep 30, 2025 | -26.82% |
| Jun 30, 2025 | 15.29% |
| Mar 31, 2025 | 14.99% |
| Dec 31, 2024 | 6.49% |
| Sep 30, 2024 | 25.52% |
| Jun 30, 2024 | 46.45% |
| Mar 31, 2024 | -24.38% |
| Dec 31, 2023 | -33.75% |
| Sep 30, 2023 | 0.78% |
| Jun 30, 2023 | -13.63% |
| Mar 31, 2023 | -0.02% |
| Dec 31, 2022 | 31.92% |
| Sep 30, 2022 | 1.63% |
| Jun 30, 2022 | 19.67% |
| Mar 31, 2022 | 34.49% |
| Dec 31, 2021 | -12.90% |
| Sep 30, 2021 | -26.90% |
| Jun 30, 2021 | 25.58% |
| Mar 31, 2021 | -32.46% |
| Dec 31, 2020 | -86.70% |
| Sep 30, 2020 | 1.02% |
| Jun 30, 2020 | -10.14% |
| Mar 31, 2020 | -13.13% |
| Dec 31, 2019 | -53.55% |
| Sep 30, 2019 | 17.18% |
| Jun 30, 2019 | -9.60% |
| Mar 31, 2019 | 12.43% |
| Dec 31, 2018 | -12.61% |
| Sep 30, 2018 | -77.91% |
| Jun 30, 2018 | 24.23% |
| Mar 31, 2018 | -106.60% |
| Dec 31, 2017 | -209.94% |
| Sep 30, 2017 | -162.17% |
| Jun 30, 2017 | -110.17% |
| Mar 31, 2017 | -235.00% |
| Dec 31, 2016 | -99.52% |
| Sep 30, 2016 | -63.92% |
| Jun 30, 2016 | -230.61% |
| Mar 31, 2016 | 312.77% |
| Dec 31, 2015 | -19.73% |
| Sep 30, 2015 | -81.68% |
| Jun 30, 2015 | -36.62% |
| Mar 31, 2015 | -61.51% |